Human Chemotherapeutic-Related Gene SNP Detection Kit （Next Generation Sequencing） GENE MUTATION AND DRUG The selectivity of chemotherapy drugs is relatively weak, as they not only kill cancer cells but also damage normal cells in the body, resulting in adverse drug reactions. The effectiveness of chemotherapy is influenced by individual patient differences, including sensitivity and tolerance to chemotherapy drugs, as well as the inherent toxicity of the drugs themselves. For example, certain genetic polymorphisms in the gene encoding for UGT1A1 can result in a decreased level of glucuronidation of the active metabolite of irinotecan, resulting in anaccumulation of the drug and increased risk for toxicity. Nowadays, genetic testing can be used to predict individual responses to specific drugs, assisting patients in selecting appropriate chemotherapy drugs, predicting treatment efficacy, and avoiding serious side effects. DETECTED GENES This test kit enables detection of 26 target genes and 33 loci, providing guidance for the evaluation of the efficacy and adverse effects of 19 first-line chemotherapy drug combinations, including toxic side effects. Detected Genes Common Chemotherapy Drugs Fluorouracil、Leucovorin、Gemcitabine、Docetaxel、 Vinorelbine、Cyclophosphamide、Doxorubicin、 Paclitaxel、Platinum-based drugs、Pemetrexed、 Capecitabine、Anthracyclines、Tamoxifen、 Etoposide、Methotrexate etc PRODUCT INFORMATION Product Name Human Chemotherapeutic-Related Gene SNP Detection Kit Core Technology RingCap® Pack Size Instruments Validated Sample Type Peripheral blood DETECTION SIGNIFICANCE By detecting chemotherapeutic drug-related genes in cancer patients, it is possible to determine the sensitivity and toxicity of chemotherapy drugs. This can provide a scientific basis for predicting the efficacy of drugs, improving the specificity of treatmen

Chemotherapy drugs Detect Genes Sample Type Patients with the GG genotype and colorectal cancer may have increased overall survival time as compared to patients with the AA genotype. Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival as compared to patients with the AG genotype No significant differences were observed in terms of overall survival and progression-free survival. Patients with colorectal cancer and AA genotype may have a decreased response to treatment as compared to patients with the GG genotype，including reduced medication...